Study: Many medicated for Alzheimer’s may not have the disease

A significant portion of people with mild cognitive impairment or dementia who are taking medication for Alzheimer’s may not actually have the disease, according to interim results of amajorstudyunderway to see how positron emission tomography, or PET, scans could change the nature of Alzheimer’s diagnosis and treatment.

The findings, presented Wednesday at the Alzheimer’s Association International Conference in London, come from a four-year study launched in 2016 that is testing over 18,000 Medicare beneficiaries with MCI or dementia to see if their brains contain the amyloid plaques that are one of the two hallmarks of the disease.

Among 4,000 people tested in the Imaging Dementiafor Amyloid Scanning study, researchers from the Memory and Aging Center at the University of California at SanFrancisco found that just 54.3 percent ofMCIpatients and 70.5 percent of dementia patients had the plaques.

Apositive test for amyloid does not mean someone has Alzheimer’s, though its presence precedes the disease and increases the risk of progression. But a negative test definitively means a person does not have it.

The findings could change theway doctors treat people in these hard-todiagnose groups and save money being spent on inappropriate medication.

“If someone had a putative diagnosis of Alzheimer’s disease, they might be on an Alzheimer’s drug like Aricept or Namenda,” said James Hendrix, the Alzheimer Association’s director of global science initiatives who co-presented the findings. “What if they had a PET scan and it showed that they didn’t have amyloid in their brain? Their physician would take them off that drug and look for something else.”

For decades, diagnosing Alzheimer’s has been a guessing game, based on looking at a person’s symptoms rather than testing for definitive evidence of the brain disorder.

A firm diagnosis was not possible untilanautopsywas performed.

A spinal tap or PET scan can detect the telltale amyloid deposits, and researchers are trying to develop a simple blood test that would do so. PET imaging can quantify the amount of amyloidandalsoshowwhere it is in a person’s brain.

Over 400 physicians enrolled their patients in the study and filled out forms describing how they would care for them based on their clinical symptoms. After seeing the PET imaging results, they changed care plans for two-thirds of the patients.

“We thoughtwewould be able to seeabouta30percent change, but we’re getting a 66 percent change, so it’s huge,” Hendrix said.